🇺🇸 FDA

Company profile · Sponsor

OnKure

OnKure Therapeutics

OKUR · NYSE pharma BOULDER, CO, USA
Pipeline
8
Drugs
0
Patents
7

Quick answer

OnKure (OKUR) is a pharma company. headquartered in BOULDER, CO, USA. listed on NYSE. NovaPharmaNews links 8 pipeline programs, 0 drugs, and 7 patents to this profile..

Company facts

Ticker OKUR
Exchange NYSE
Company type pharma
Headquarters BOULDER, CO, USA
SEC CIK 0001637715

Pipeline (8)

Search pipeline →

  1. REN001

    OnKure

    Primary Mitochondrial Myopathy

    phase 3 small molecule terminated

    2 trials

  2. Mavodelpar

    OnKure

    Primary Mitochondrial Myopathy

    phase 2 small molecule completed

    1 trial

  3. OKI-179 + binimetinib

    OnKure

    RAS Mutation

    phase 2 small molecule completed

    1 trial

  4. First-in-Human Study of OKI-219 Alone and in Combination with Other Therapies in Patients with Solid Tumors / Breast Cancer

    OnKure

    Advanced Solid Tumors, Advanced Breast Cancer

    phase 1 other active

    1 trial

  5. Low Dose REN001

    OnKure

    Fatty Acid Oxidation Disorders

    phase 1 small molecule completed

    1 trial

  6. OKI-179

    OnKure

    Advanced Solid Tumors

    phase 1 small molecule completed

    1 trial

  7. OKI-219

    OnKure

    Advanced Cancer

    phase 1 small molecule active

    1 trial

  8. REN001

    OnKure

    McArdle Disease

    phase 1 small molecule completed

    1 trial

Patents (7)

Search patents →

  1. US 12252511

    Process for the preparation of cyclic depsipeptides

    Expires Mon Mar 13 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 11739123

    Process for the preparation of cyclic depsipeptides

    Expires Mon Aug 24 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 11339150

    Benzimidazole compounds as HDAC6 inhibitors

    Expires Mon May 19 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 11203602

    Thioester prodrugs of macrocycles as inhibitors of histone deacetylases

    Expires Mon Dec 16 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 11053284

    Process for the preparation of cyclic depsipeptides

    Expires Mon Jul 01 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 10689419

    Process for the preparation of cyclic depsipeptides

    Expires Mon Jun 18 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 10100089

    Process for the preparation of cyclic depsipeptides

    Expires Mon Oct 11 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is OnKure?

OnKure (OKUR) is a pharma company. headquartered in BOULDER, CO, USA. listed on NYSE. NovaPharmaNews links 8 pipeline programs, 0 drugs, and 7 patents to this profile..

What pipeline programs does OnKure sponsor?

We track 8 ClinicalTrials.gov-linked programs for OnKure, including REN001 and 7 more. Open each program for phase, modality, NCT IDs, and indication details.

Where does OnKure company data come from?

Profiles combine SEC EDGAR (CIK/ticker), ClinicalTrials.gov sponsor links, FDA drug records, and USPTO patent metadata. See our data sources page. This profile is for professional reference, not investment advice.